ADC (Antibody-Drug Conjugate) Deal Benchmarks in Oncology

Median Upfront

$411M

Range: $229M - $582M

Total Deal Value

$2.6B

Range: $1.7B - $3.5B

Royalty Rate

13.6% - 22.2%

Tiered up to 26.2%

Dev Milestones

$550M

Range: $367M - $736M

Model Your Deal

Market Analysis

ADC (Antibody-Drug Conjugate) therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 adc (antibody-drug conjugate) asset in oncology is $411M, with total deal values reaching $2.6B. Development milestones average $550M, while regulatory milestones contribute $880M.

The oncology adc (antibody-drug conjugate) landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for adc (antibody-drug conjugate) oncology deals range from 13.6% to 22.2% at the base tier, with tiered escalation reaching 17.6%-26.2% on blockbuster sales. Commercial milestones averaging $770M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a adc (antibody-drug conjugate) oncology licensing deal?

Based on our analysis, Phase 2 adc (antibody-drug conjugate) licensing deals in oncology average $411M in upfront payments, with a range of $229M to $582M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for adc (antibody-drug conjugate) oncology transactions?

The median total deal value for Phase 2 adc (antibody-drug conjugate) assets in oncology is $2.6B, ranging from $1.7B to $3.5B. This includes development milestones ($550M), regulatory milestones ($880M), and commercial milestones ($770M).

What royalty rates are standard for adc (antibody-drug conjugate) deals in oncology?

Base royalty rates for adc (antibody-drug conjugate) oncology transactions range from 13.6% to 22.2%, with tiered escalations reaching 17.6%-26.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in adc (antibody-drug conjugate) oncology deals?

ADC (Antibody-Drug Conjugate) oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($550M) make up the largest share, followed by commercial milestones ($770M) and regulatory milestones ($880M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included